EXPRESSION OF HEPATOCYTE GROWTH FACTOR AND C-MET RECEPTOR IN STROMAL FIBROBLASTS AND TUMOR CELLS OF ENDOMETRIAL CARCINOMA
DOI:
https://doi.org/10.15407/exp-oncology.2023.01.079Keywords:
c-Met, endometrial carcinoma, HGF, stromal fibroblasts, tumor cells.Abstract
Background: HGF/c-Met is one of the main signaling pathways that ensure communication between epithelial cells and components of the tumor microenvironment determining the invasive and metastatic potential of many cancers. However, the significance of HGF and c-Met in endometrial carcinoma (ECa) progression remains unclear. Aim: To evaluate copy number variations as well as expression of the c-Met receptor and its ligand HGF in endometrial carcinomas considering the clinical and morphological characteristics of ECa. Materials and Methods: The study was conducted on ECa samples of 57 patients, among which 32 had lymph nodes and/or distant metastasis. The copy number of c-MET gene was estimated by qPCR. The expression of HGF and c-Met in tissue samples was determined by the immunohistochemical method. Results: Amplification of c-MET gene was detected in 10.5% of the ECa cases. In most carcinomas, a combined expression pattern of HGF and c-Met was established, in which co-expression of these markers was observed in tumor cells, and the content of HGF+ fibroblasts increased in the stroma. The expression of HGF in tumor cells was associated with the tumor differentiation grade and was higher in G3 ECa (p = 0.041). The number of HGF+ fibroblasts in the stromal component increased in the ECa cases with metastasis compared to the cases without metastasis (p = 0.032). The content of stromal c-Met+ fibroblasts was higher in deeply invasive carcinomas of patients with metastases than in tumors with invasion of < 1/2 myometrium (p = 0.035). Conclusion: Increased expression of HGF and c-Met in stromal fibroblasts of endometrial carcinomas is associated with metastasis in patients with ECa and deep invasion of the tumor into the myometrium, and can contribute to the aggressive course of the disease.
References
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–249. doi: 10.3322/caac.21660
Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol 2014; 15: e268–e278. doi: 10.1016/S1470-2045(13)70591-6
Yen TT, Wang TL, Fader AN, et al. Molecular classification and emerging targeted therapy in endometrial cancer. Int J Gynecol Pathol 2020; 39: 26–35. doi: 10.1097/PGP.0000000000000585
Buchynska LG, Glushchenko NM, Nesina IP, et al. Molecular phenotype of high-grade endometrioid carcinoma of the endometrium. Exp Oncol 2020; 42: 300–305. doi: 10.32471/exp-oncology.2312-8852.vol-42-no-4.15450
Neophytou CM, Panagi Ma, Stylianopoulos T, Papageorgis P. The role of tumor microenvironment in cancer metastasis: molecular mechanisms and therapeutic opportunities. Cancers (Basel) 2021; 13: 2053. doi: 10.3390/cancers13092053
Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9: 239–252. doi: 10.1038/nrc2618
Sahoo SS, Zhang XD, Hondermarck H, Tanwar PS. The emerging role of the microenvironment in endometrial cancer. Cancers (Basel) 2018; 10: 408. doi: 10.3390/cancers10110408
Buchynska LG, Movchan OM, Iurchenko NP. Expression of chemokine receptor CXCR4 in tumor cells and content of CXCL12+-fibroblasts in endometrioid carcinoma of endometrium. Exp Oncol 2021; 43: 135–141. doi: 10.32471/exp-oncology.2312-8852.vol-43-no-2.16240
Moosavi F, Giovannetti E, Saso L, Firuzi O. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers. Crit Rev Clin Lab Sci 2019; 56: 533–566. doi: 10.1080/10408363.2019.1653821
Fu J, Su X, Li Z, et al. HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence. Oncogene 2021; 40: 4625–4651. doi: 10.1038/s41388-021-01863-w
Maroun CR, Rowlands T. The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance. Pharmacol Ther 2014; 142: 316–338. doi: 10.1016/j.pharmthera.2013.12.014
Sugawara J, Fukaya T, Murakamiet T, et al. Hepatocyte growth factor stimulated proliferation, migration, and lumen formation of human endometrial epithelial cells in vitro. Biol Reprod 1997; 57: 936–942. doi: 10.1095/biolreprod57.4.936
Zhang X. Hepatocyte growth factor system in the mouse uterus: variation across the estrous cycle and regulation by 17-beta-estradiol and progesterone. Biol Reprod 2010; 82: 1037–1048. doi: 10.1095/biolreprod.109.079772
Spina A, De Pasquale V, Cerulo G, et al. HGF/c-MET axis in tumor microenvironment and metastasis formation. Biomedicines 2015; 3: 71–88. doi: 10.3390/biomedicines3010071
Felix AS, Edwards RP, Stone RA, et al. Associations between hepatocyte growth factor, c-Met, and basic fibroblast growth factor and survival in endometrial cancer patients. Br J Cancer 2012; 106: 2004–2009. doi: 10.1038/bjc.2012.200
Bishop EA, Lengyel ER, Yamada SD, et al. The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma. Gynecol Oncol 2011; 121: 218–223. doi: 10.1016/j.ygyno.2010.11.031
Wagatsuma S, Konno R, Sato S, Yajima A. Tumor angiogenesis, hepatocyte growth factor, and c-Met expression in endometrial carcinoma. Cancer 1998; 82: 520–530. doi: 10.1002/(sici)1097-0142(19980201)82:3<520::aid-cncr14>3.0.co;2-3
Rudenko EE, Lapska YV, Gerashchenko GV, et al. Heterozygous deletions are main cause of expression alterations of PPM1M and PRICLE2 genes in human clear cell renal cell carcinomas. Biopolym Cell 2015; 31: 29–33.
Koh YW, Lee HJ, Ahn JH, et al. MET expression is associated with disease-specific survival in breast cancer patients in the neoadjuvant setting. Pathol Res Pract 2014; 210: 494–500. https://doi.org/10.1016/j.prp.2014.04.002
Edakuni G, Sasatomi E, Satoh T, et al. Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma. Pathol Int 2001; 51:172–178. doi: 10.1046/j.1440-1827.2001.01182.x
Tokunou M, Niki T, Eguchi K, et al. c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma. Am J Pathol 2001; 158: 1451–1463. doi: 10.1016/S0002-9440(10)64096-5
Jones NL, Xiu J, Chatterjee-Paer S, et al. Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomas. Int J Cancer 2017; 140:1396–1404. doi: 10.1002/ijc.30537
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
